Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
NCT02032836
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG:
lloprost(Ventavis,BAYQ6252, 20 µg/mL)
DRUG:
lloprost(Ventavis,BAYQ6252, 10 µg/mL)
Sponsor
Bayer